Skip to content

Opko Health OPK Pharmaceutical — Goodwill

Similar metrics at other companies

Bausch + Lomb logo
BLCOPharmaceuticals — Goodwill
$731M+8.0%
Baxter International logo
BAXPharmaceuticals — Goodwill
$569M+2.2%
Johnson & Johnson logo
JNJPharmaceutical — Goodwill (Note 3)
$14.81B+35.8%
AptarGroup logo
ATRPharma — Goodwill
$534.34M
Johnson & Johnson logo
JNJPharmaceutical — Goodwill, related to acquisitions
$0
Cardinal Health logo
CAHPharmaceutical and Specialty Solutions — Goodwill
$9.67B+25.0%

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.14B+11.5%
P/S+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's pharmaceutical — goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's pharmaceutical — goodwill?
Opko Health (OPK) reported pharmaceutical — goodwill of $318.83M in Q1 2026.
What is the long-term trend for Opko Health's pharmaceutical — goodwill?
Over 3 years (2021 to 2024), Opko Health's pharmaceutical — goodwill has grown at a 13.2% compound annual growth rate (CAGR), from $863.45M to $1.25B.
What does pharmaceutical — goodwill mean?
The net carrying value of goodwill associated with the pharmaceutical segment after accounting for acquisitions, divestitures, and impairment charges. It serves as a key indicator of the segment's historical acquisition activity and current valuation assessment.